Top

Open Access 07-05-2024 | Opioids | Original Article

CPL-01, an investigational long-acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair

Authors: H. T. Xu, J. Zimmerman, T. Bertoch, L. Chen, P. J. Chen, E. Onel

Published in: Hernia

Abstract

Background

There is an unmet medical need for effective nonopioid analgesics that can decrease pain while reducing systemic opioid use. CPL-01, an extended-release injectable formulation of ropivacaine, is designed to safely provide analgesia and reduce or eliminate opioid use in the postoperative period.

Methods

Subjects undergoing open inguinal hernia with mesh were prospectively randomized to 1 of 3 doses of CPL-01 (10, 20, or 30 ml of 2% CPL-01, n = 14, 12, and 14, respectively), Naropin (150 mg, n = 40), or saline placebo (n = 13) infiltrated into the surgical site prior to closure. Pain and rescue medication usage was assessed, and Numeric Rating Scale (NRS) pain scores were adjusted for opioid usage using windowed worst observation carried forward (wWOCF) imputation. The primary efficacy endpoint was the mean area under the curve (AUC) of the NRS pain intensity scores with activity.

Results

Ninety-three subjects were treated, and 91 subjects completed 72 h of post-operative monitoring. Subjects who received the highest dose of CPL-01 in Cohort 3 showed a clinically meaningful reduction in postoperative pain intensity scores, which was the lowest value for any treatment in all cohorts, showing a trend towards statistical significance as compared to the pooled placebo group (p = 0.08), and numerically better than the 40 subjects who received Naropin. Opioid use through 72 h in subjects who received CPL-01 in Cohort 3 was approximately half of that shown in the placebo and Naropin groups; approximately 2/3 of the CPL-01 subjects (9/14) required no opioids at all through the first 72 h after the operation. More CPL-01 subjects avoided severe pain and were ready for discharge earlier than other groups. CPL-01 was safe and well-tolerated, with no clinically meaningful safety signals, and showed predictable and consistent extended-release pharmacokinetics.

Conclusion

Results suggest that CPL-01 may be the first long-acting ropivacaine to address postoperative pain while reducing the need for opioids.

Available only for authorised users

Tan M, Law LS, Gan TJ (2015) Optimizing pain management to facilitate enhanced recovery after surgery pathways. Can J Anaesth 62:203–218. https://doi.org/10.1007/s12630-014-0275-xCrossRefPubMed

Skolnick P (2018) The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol 58:143–159. https://doi.org/10.1146/annurev-pharmtox-010617-052534CrossRefPubMed

Mitra S, Carlyle D, Kodumudi G et al (2018) New advances in acute postoperative pain management. Curr Pain Headache Rep 22:35. https://doi.org/10.1007/s11916-018-0690-8CrossRefPubMed

Mariano ER, Dickerson DM, Szokol JW et al (2022) A multisociety organizational consensus process to define guiding principles for acute perioperative pain management. Reg Anesth Pain Med 47:118–127. https://doi.org/10.1136/rapm-2021-103083CrossRefPubMed

Chou R, Gordon DB, de Leon-Casasola OA et al (2016) Management of postoperative pain: a clinical practice guideline from the american pain society, the american society of regional anesthesia and pain medicine, and the american society of anesthesiologists’ committee on regional anesthesia, executive committee, and administrative council. J Pain 17:131–157. https://doi.org/10.1016/j.jpain.2015.12.008CrossRefPubMed

Beverly A, Kaye AD, Ljungqvist O et al (2017) Essential elements of multimodal analgesia in Enhanced Recovery After Surgery (ERAS) guidelines. Anesthesiol Clin 35:e115–e143. https://doi.org/10.1016/j.anclin.2017.01.018CrossRefPubMed

Joshi G, Gandhi K, Shah N et al (2016) Peripheral nerve blocks in the management of postoperative pain: challenges and opportunities. J Clin Anesth 35:524–529. https://doi.org/10.1016/j.jclinane.2016.08.041CrossRefPubMed

Gabriel RA, Swisher MW, Sztain JF et al (2019) State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. Expert Opin Pharmacother 20:949–961. https://doi.org/10.1080/14656566.2019.1583743CrossRefPubMed

Coppens SJR, Zawodny Z, Dewinter G et al (2019) In search of the holy grail: poisons and extended release local anesthetics. Best Pract Res Clin Anaesthesiol 33:3–21. https://doi.org/10.1016/j.bpa.2019.03.002CrossRefPubMed

10.

Zink W, Graf BM (2004) Benefit-risk assessment of ropivacaine in the management of postoperative pain. Drug Saf 27:1093–1114. https://doi.org/10.2165/00002018-200427140-00003CrossRefPubMed

11.

McGlade DP, Kalpokas MV, Mooney PH et al (1998) A comparison of 0.5% ropivacaine and 0.5% bupivacaine for axillary brachial plexus anaesthesia. Anaesth Intensive Care 26:515–520. https://doi.org/10.1177/0310057x9802600507CrossRefPubMed

12.

Kaur A, Singh RB, Tripathi RK et al (2015) Comparision between bupivacaine and ropivacaine in patients undergoing forearm surgeries under axillary brachial plexus block: a prospective randomized study. J Clin Diagn Res 9:Uc01–Uc06. https://doi.org/10.7860/jcdr/2015/10556.5446CrossRefPubMedPubMedCentral

13.

Fanelli G, Casati A, Beccaria P et al (1998) A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 87:597–600. https://doi.org/10.1097/00000539-199809000-00019CrossRefPubMed

14.

Wang RD, Dangler LA, Greengrass RA (2001) Update on ropivacaine. Expert Opin Pharmacother 2:2051–2063. https://doi.org/10.1517/14656566.2.12.2051CrossRefPubMed

15.

Onel E, Crean C, Chen L et al (2022) CPL-01, a novel ropivacaine formulation, demonstrates safety and extended release characteristics in abdominoplasty. Anesthes Analg 135(5):909

16.

Gitman M, Barrington MJ (2018) Local anesthetic systemic toxicity: a review of recent case reports and registries. Reg Anesth Pain Med 43:124–130. https://doi.org/10.1097/AAP.0000000000000721CrossRefPubMed

17.

Vasques F, Behr AU, Weinberg G et al (2015) A review of local anesthetic systemic toxicity cases since publication of the american society of regional anesthesia recommendations: to whom it may concern. Reg Anesth Pain Med 40:698–705. https://doi.org/10.1097/AAP.0000000000000320CrossRefPubMed

18.

Di Gregorio G, Neal JM, Rosenquist RW et al (2010) Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med 35:181–187. https://doi.org/10.1097/aap.0b013e3181d2310bCrossRefPubMed

19.

Food and Drug Administration: Center for Drug Evaluation and Research (2022) Development of non-opioid analgesics for acute pain. Guidance for Industry, DRAFT GUIDANCE

20.

Food and Drug Administration: Center for Drug Evaluation and Research (2023) Development of local anesthetic drug products with prolonged duration of effect. Silver Spring, draft guidance, Guidance for Industry

21.

Salaffi F, Stancati A, Silvestri CA et al (2004) Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 8:283–291. https://doi.org/10.1016/j.ejpain.2003.09.004CrossRefPubMed

22.

Brummett CM, Waljee JF, Goesling J et al (2017) New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg 152:e170504. https://doi.org/10.1001/jamasurg.2017.0504CrossRefPubMedPubMedCentral

23.

Shah A (2017) Characteristics of initial prescription episodes and likelihood of long-term opioid use — united states 2006–2015. Morb Mortal Wkly Rep 66(10):265–269CrossRef

24.

Mallow PJ, Belk KW, Topmiller M et al (2018) Geographic variation in hospital costs, payments, and length of stay for opioid-related hospital visits in the USA. J Pain Res 11:3079–3088. https://doi.org/10.2147/jpr.S184724CrossRefPubMedPubMedCentral

25.

Rhyan C (2017) The potential societal benefit of eliminating opioid overdoses, deaths, and substance use disorders exceeds $95 billion per year. Altarum

26.

Hammoud M, Gerken J (2023) Inguinal Hernia. Treasure Island (FL), StatPearls

27.

Perez AJ, Petro CC, Higgins RM et al (2022) Predictors of low and high opioid tablet consumption after inguinal hernia repair: an ACHQC opioid reduction task force analysis. Hernia 26:1625–1633. https://doi.org/10.1007/s10029-022-02661-3CrossRefPubMed

28.

Knight AW, Habermann EB, Ubl DS et al (2019) Opioid utilization in minimally invasive versus open inguinal hernia repair. Surgery 166:752–757. https://doi.org/10.1016/j.surg.2019.05.012CrossRefPubMed

29.

Millard JL, Moraney R, Childs JC et al (2020) opioid use after inguinal and ventral hernia repair. Am Surg 86:965–970. https://doi.org/10.1177/0003134820942179CrossRefPubMed

30.

Higgins RM, Petro CC, Warren J et al (2022) The opioid reduction task force: using the ACHQC data registry to combat an epidemic in hernia patients. Hernia 26:855–864. https://doi.org/10.1007/s10029-021-02556-9CrossRefPubMed

31.

Howard R, Gunaseelan V, Brummett C et al (2022) New persistent opioid use after inguinal hernia repair. Ann Surg 276:e577–e583. https://doi.org/10.1097/SLA.0000000000004560CrossRefPubMed

32.

Reinhorn M, Dews T, Warren JA et al (2022) Utilization of a national registry to influence opioid prescribing behavior after hernia repair. Hernia 26:847–853. https://doi.org/10.1007/s10029-021-02495-5CrossRefPubMed

33.

Casati A, Santorsola R, Cerchierini E et al (2001) Ropivacaine. Minerva Anestesiol 67:15–19PubMed

Title: CPL-01, an investigational long-acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair
Authors: H. T. Xu
J. Zimmerman
T. Bertoch
L. Chen
P. J. Chen
E. Onel
Publication date: 07-05-2024
Publisher: Springer Paris
Keywords: Opioids
Opioids
Inguinal Hernia
Published in: Hernia
Print ISSN: 1265-4906
Electronic ISSN: 1248-9204
DOI: https://doi.org/10.1007/s10029-024-03047-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CPL-01, an investigational long-acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content